Iterion Therapeutics is a clinical-stage biopharmaceutical company based in Houston, TX, dedicated to revolutionizing healthcare through innovative drug discovery. Their lead product, tegavivint, is a first-in-class small molecule inhibitor that targets Transducin Beta-like Protein 1 (TBL1), a key component of the Wnt beta-catenin signaling pathway implicated in various types of cancers. By binding to TBL1 and displacing beta-catenin, tegavivint inhibits oncogenic gene expression, offering a promising approach to treating cancer.
Iterion Therapeutics has already demonstrated the safety, pharmacodynamic effects, and clinical activity of tegavivint in a completed Phase 1 clinical trial. They are currently enrolling patients for a company-sponsored clinical trial in hepatocellular carcinoma, a cancer type with a high prevalence of Wnt beta-catenin mutations and significant unmet clinical needs. Additionally, Iterion has established collaborative relationships with leading institutions to further investigate tegavivint's potential in complementary investigator-sponsored trials.
Generated from the website
